Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSD | A5PKW4 | 6/20 | 0.52 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19084545 | 0.90 | PSD (0.50) | PSDCNR1NPC1MAPTNPSR1 | |
| SCHEMBL13516328 | 0.84 | TP53 (0.48) | NPC1GAAMAPTNPSR1MEN1 | |
| SCHEMBL1613449 | 0.84 | TP53 (0.48) | NPC1GAAMAPTNPSR1MEN1 | |
| SCHEMBL13515966 | 0.84 | MAPT (0.46) | NPC1GAAMAPTNPSR1MEN1 | |
| SCHEMBL13516176 | 0.83 | MAPT (0.41) | GAAMAPTKMT2A | |
| SCHEMBL19084515 | 0.81 | PSD (0.49) | PSDNPY5RGAA | |
| SCHEMBL13516353 | 0.79 | NPY5R (0.44) | PSDCNR1NPY5RNPC1GAA | |
| SCHEMBL19084590 | 0.79 | PSD (0.53) | PSDNPY5R | |
| SCHEMBL19084549 | 0.79 | PSD (0.45) | PSDNPC1MAPTMEN1RAB9A | |
| SCHEMBL1614418 | 0.79 | PSD (0.45) | PSDNPC1MAPTMEN1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10849901-B2 | Arf6 inhibitors and methods of synthesis and use thereof | NAVIGEN, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20170189405-A1 | ARF6 INHIBITORS AND METHODS OF SYNTHESIS AND USE THEREOF | NAVIGEN, INC. (US) | 2017-07-06 | — | — | US | disclosed |
| US-20170189405-A1 | ARF6 INHIBITORS AND METHODS OF SYNTHESIS AND USE THEREOF | NAVIGEN, INC. (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170189405-A1 | ARF6 INHIBITORS AND METHODS OF SYNTHESIS AND USE THEREOF | ARF6, ARF1, ARFIP2 | PSD 211/4885CNR1 3560/4885NPY5R 4566/4885 |
| US-10849901-B2 | Arf6 inhibitors and methods of synthesis and use thereof | ARF6, ARF1, ARFIP2 | PSD 211/4885CNR1 3560/4885NPY5R 4566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.